Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 7/20 | 0.47 |
| ▸ | PDE1A | P54750 | 5/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | CCR9 | P51686 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17735994 | 0.86 | L3MBTL1 (0.52) | PDE1BPDE1APDE1CAVPR1ANPC1 | |
| SCHEMBL17684539 | 0.84 | CCR9 (0.56) | CCR9 | |
| SCHEMBL2359301 | 0.80 | CYP2C19 (0.51) | GPR35SMN1; SMN2L3MBTL1CCR9TP53 | |
| SCHEMBL16304459 | 0.79 | GPR35 (0.50) | GPR35SMN1; SMN2L3MBTL1CCR9TP53 | |
| SCHEMBL17735991 | 0.77 | GPR35 (0.48) | GPR35SMN1; SMN2L3MBTL1CCR9TP53 | |
| SCHEMBL27757298 | 0.69 | NOTUM (0.43) | — | |
| SCHEMBL1447738 | 0.67 | PDE1C (0.39) | PDE1BPDE1APDE1CSMN1; SMN2 | |
| SCHEMBL4418297 | 0.66 | HPGDS (0.51) | GPR35RAB9ASMN1; SMN2 | |
| SCHEMBL15462252 | 0.65 | GPR35 (0.57) | GPR35SMN1; SMN2L3MBTL1CCR9TP53 | |
| SCHEMBL16304457 | 0.65 | L3MBTL1 (0.58) | NPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855257-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9593081-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | PDE1B 1440/4885PDE1A 1362/4885PDE1C 1890/4885 |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | PDE1B 1371/4885PDE1A 1241/4885PDE1C 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.